After U.S. FDA Action, Investors Take Caraco To Court Alleging Violation Of Securities Laws
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A group of shareholders of U.S.-based generic drug maker Caraco Pharmaceutical has taken the company to court alleging that it violated securities laws by "recklessly disregarding May 29, 2008 and June 25, 2009 that their public statements concerning Caraco's business, operations and prospects were materially false and misleading." One of India's top generic drug makers, Sun Pharma, owns a majority 76 percent equity stake in Caraco
You may also be interested in...
Inside India’s Most Valued Pharma Company: Sun Pharma Chief Dilip Shanghvi Lays Out Future Growth Plans
Sun Pharma chief will look for opportunities in emerging markets, but buyouts will not be large.
FDA Fires Warning Letter To Sun Pharma; Says Corrections At Cranbury Site Inadequate
MUMBAI - Sun Pharmaceuticals - India's largest company by market capitalization - has been issued a warning letter by U.S. FDA for significant violations of good manufacturing practices at its Cranbury-based manufacturing site
FDA Fires Warning Letter To Sun Pharma; Says Corrections At Cranbury Site Inadequate
MUMBAI - Sun Pharmaceuticals - India's largest company by market capitalization - has been issued a warning letter by U.S. FDA for significant violations of good manufacturing practices at its Cranbury-based manufacturing site